The NEAT 001 trial was an open-label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naïve subjects: darunavir/r + tenofovir/emitricitabine vs. darunavir/r + raltegravir.
EudraCT number: 2009-015113-44.
Legal sponsor: Inserm - ANRS (Institut national de la santé et de la recherche médicale- Agence nationale de recherches sur le sida et les hépatites virales (ANRS), (trial no. ANRS 143).
Co-sponsor: European AIDS treatment network NEAT, funded by the European Commission through FP6 Network of Excellence programme.
NEAT (European AIDS Treatment Network) is a EU funded initiative with 37 partner institutions of which CHIP is one. Neat will promote transnational clinical research from proof-of-concept to phase III-IV strategic effectiveness trials. NEAT´s mission is to strengthen European HIV clinical research capacity by building a clinical and laboratory network in HIV therapeutics.
Newsletter April 2013
Newsletter September 2012
Newsletter October/November 2011